IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 1  
CLINICAL STUDY PROTOCOL 
 
 
A RANDOMIZED, DOUBLE-BLIND,  PLACEBO-CONTROLLED PILOT 
STUDY TO ASSESS THE SAFETY AND EFFICACY OF IFETROBAN FOR 
THE TREATMENT OF PORTAL HYPERTENSION IN CIRRHOTIC 
PATIENTS 
 
Study Number: CPI-IFE-005 
 
 
Protocol Version 
 
Version Number:  Amendment 02 
Final:   24 JULY 2017  
  
 
CONFIDENTIALITY STATEMENT 
The information in this document contains trade secrets and com mercial information that are 
privileged or confidential and may not be disclosed unless such  disclosure is required by applicable 
laws and regulations. In any event, persons to whom the informa tion is disclosed must be informed 
that the information is privil eged or confidential and may not be further disclosed by them. These 
restrictions on disclosure will apply equally to all future inf ormation supplied to you which is 
indicated as privileged or confidential. 
  
 
RESPONSIBLE PERSONNEL 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 2 Sponsor - Medically Responsible Person  Sponsor’s Coordinating Office 
   
Todd Rice, MD  Leo Pavliv, R.Ph 
Director, Medical Affairs  Executive VP, Operations and Chief 
Development Officer 
Cumberland Pharmaceuticals Inc.  Cumberland Pharmaceuticals Inc . 
2525 West End Avenue, Suite 950  2525 West End Avenue, Suite 95 0 
Nashville, TN 37203  Nashville, TN 37203 USA  USA 
   
Tel.: 615-255-0068   Tel.: 615-255-0068  
Fax.: 866-438-2372  Fax.: 866-438-2372 
  
lpavliv@cumberlandpharma.com 
   
   
Sponsor’s Clinical Operations   Coordinating Investigator    
Jerry Fox, DVM   Don Rockey, MD 
Manager, Clinical Affairs  Professor and Chairman, Department of 
Medicine 
Cumberland Pharmaceuticals Inc.  Medical University of South Carolina 
2525 West End Avenue, Suite 950  96 Jonathan Lucas Street 
Nashville, TN 37203  Suite 803, MSC 623 
USA  Charleston, SC 29425 
  Telephone: 843-792-1020 
Tel.: 615-255-0068   rockey@musc.edu 
Fax.: 866-438-2372   
jfox@cumberlandpharma.com      
 
 
 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 3 1 INVESTIGATOR’S STATEMENT 
I have read and agree to Amendment 02, dated 24Jul2017, of Prot ocol CPI-IFE-005, “A 
randomized, double-blind, placebo-controlled pilot study to ass ess the safety and efficacy of 
ifetroban for the treatment of portal hypertensi on in cirrhotic  p a t i e n t s ” .  I  a m  a w a r e  o f  m y  
responsibilities as an Investigat or under the guidelines of Goo d Clinical Practice (GCP), local 
regulations (as applicable) and the study protocol. I agree to conduct the study according to these 
guidelines and to appropriately direct and assist the staff und er my control, who will be involved 
in the study. 
 
Principal Investigator 
Signature:  
 
   
 <<name>>  Date of Signature 
 <<address>> 
 
 
 
 <<phone>> 
 
Sponsor Signature 
Signature:  
 
   
 Todd Rice, MD  Date of Signature 
 Director, Medical Affairs  
  
Signature:  
 
   
 Leo Pavliv, R.Ph  Date of Signature 
 Executive Vice President, Operations & Chief Development Offic er 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 4 2 SYNOPSIS 
Name of Sponsor: 
Cumberland Pharmaceuticals Inc. Finished Product: 
Ifetroban Sodium Injection and  Oral Capsule Active Ingredient: 
Ifetroban Sodium 
Title of Study: A randomized, double-blind, place bo-controlled pilot study to a ssess the safety 
and efficacy of ifetroban for the  treatment of portal hypertens ion in cirrhotic patients  
Coordinating Center: Medical University of South Carolina  
Expected Study Duration:  12 months  Phase of Development: II 
Objectives: 
To evaluate the following in c irrhotic patients with portal hyp ertension that are treated with 
ifetroban:  
 Safety 
 Portal pressure 
 Serum liver enzymes 
 Surrogate markers of liver fibrosis and inflammation 
 Occurrence of variceal bleeds 
Methodology: This is a multicenter, double-b lind randomized study to evaluat e the efficacy and 
safety of ifetroban treatment  in patients wit h cirrhosis.  
Number of subjects (planned): Thirty patients:  20 assigned to ifetroban; 10 on placebo  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 5 Diagnosis and main criteria for inclusion: 
1. Cirrhosis defined by histology or historical mean HVPG > 7 mm H g, or confirmed by 
liver stiffness measurement (LSM) above diagnostic threshold (1 5 kPa for Vibration 
Controlled Transient Elastography (VCTE) or 6.7 kPa for Magneti c Resonance 
Elastography (MRE) AND evidence o f splenomegaly o r collaterals OR platelet count 
below 150 x 103 with AST>ALT  
2. At least two stable baseline values for AST, ALT, ALP and bilir ubin taken at screening 
and between 15 and 90 days prior.  Stable is defined as values having a difference < 40 
U/L for AST and ALT, < 60 U/L f or ALP and < 3.0 mg/dL for total  serum bilirubin  
3. Baseline mean hepatic venous pr essure gradient between 8 and 18  mmHg, inclusive 
Main criteria for exclusion:   
4. Less than 18 or more than 70 years of age 
5. Portal or splenic thrombosis 
6. Transjugular intrahepatic shunt (TIPS) 
7. Active GI/variceal hemorrhage within the last 60 days 
8. Hemodialysis 
9. Child-Pugh score > 12, calculat ed within 30 days of enrollment 
10. MELD-Na score > 20 
11. Platelet count < 60 x 103/µL 
12. History of bleeding diathesis or  risk factors based on patient or familial history, other than 
cirrhosis and its sequelae 
13. Current acute kidney injury (AK I), chronic kidney disease (CKD)  or hepatorenal 
syndrome (HRS) or a ba seline SCr > 2.0 mg/dL 
14. MI in the 90 days prior to enrollment 
15. Current need for endothelin recepto r antagonists, somatostatin analogues or prostanoids, 
treatment for viral hepatitis, anticoa gulant or antiplatelet dru gs. 
Investigational Medicinal Product (IMP), dose and mode of admin istration: Loading IV 
infusion of 150 mg ifetroban or placebo, followed by 250 mg ife troban or placebo taken orally 
each day for 90 days 
Duration of treatment: 90 da ys 
Criteria for evaluation : 
SAFETY EV ALUATION 
 Incidence and severit y of adverse events 
EFFICACY EV ALUATION 
 Hepatic Venous Pressure Gradient  
 AST/ALT levels 
 Aspartate Aminotransferase /Platelet Ratio Index (APRI) 
 measurements of fibrosis a nd inflammatory biomarkers 
 incidence and severit y of variceal bleeds 
Statistical methods: Statistics will be descriptive.  Continuous safety and efficacy data will be 
summarized in tables comparing pr oportions or percentages of pa tients in the active treatment 
group with those of the placebo patients. Standard deviation or  standard error will also be 
calculated. All treated patients will be included in the safety  analysis population.  
 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 6 3 TABLE OF CONTENTS  
1  INVESTIGATOR’S STATEMENT ...................................... ....................................... 3  
2  SYNOPSIS ...................................................... ............................................................ 4  
3  TABLE OF CONTENTS ............................................. ................................................ 6  
 LIST OF TABLES ............................................... ........................................................ 8  
4  LIST OF ABBREVIATIONS AND DEFINITION OF TERMS ................. ................ 9  
5  INTRODUCTION .................................................. ................................................... 11  
5.1  Background Information ........................................ ............................................... 11  
5.2  Stage of Development .......................................... ................................................. 12  
5.3  Patient Population ............................................ ...................................................... 12  
5.4  Trial Rationale ............................................... ........................................................ 12  
5.5  Risk-Benefit Assessment ....................................... ................................................ 12  
6  STUDY OBJECTIVES .............................................. ................................................ 13  
6.1  Study Endpoints ............................................... ...................................................... 13  
7  STUDY DESCRIPTION ............................................. .............................................. 14  
7.1  Study Design .................................................. ....................................................... 14  
7.2  Randomization and Blinding Conditions and Methods ............. ............................ 14  
7.2.1  Randomization ................................................. .................................................. 14  
7.2.2  Unblinding Conditions and Procedures .......................... ................................... 15  
7.3  Drugs and Dosages ............................................. ................................................... 15  
7.3.1  Identification and Description of Test Agents ................. .................................. 15  
7.3.1.1  Ifetroban Injection ........................................... ............................................... 15  
7.3.1.2  Oral Ifetroban Capsules ....................................... .......................................... 16  
7.3.1.3  Oral Placebo Capsules ......................................... .......................................... 16  
7.3.2  IMP Preparation and Dosing Instructions ....................... ................................... 16  
7.3.2.1  Ifetroban or Placebo Injection ................................ ........................................ 16  
7.3.2.2  Oral Ifetroban or Placebo ..................................... .......................................... 17  
7.3.3  Drug Accountability Procedures ................................ ........................................ 18  
7.4  Selection of Study Population ................................. .............................................. 19  
7.4.1  Inclusion Criteria ............................................ ................................................... 19  
7.4.2  Exclusion Criteria ............................................ .................................................. 19  
7.5  Prior and Concomitant Therapy ................................. ........................................... 21  
7.5.1  Excluded Medications/P rocedures/Therapy ....................... ............................... 21  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 7 7.5.2  Dietary and Fasti ng Requirements .............................. ...................................... 21  
8  EXPERIMENTAL PROCEDURES ....................................... ................................... 22  
8.1  Overview – Schedule of Time and Events ........................ .................................... 22  
8.2  Measurements and Evaluations .................................. ........................................... 24  
8.2.1  Description of Key Study Assessments .......................... ................................... 24  
8.2.1.1  Hepatic Venous Pressure Gradi ent (HVPG) Measurement ........... ................ 24  
8.2.1.2  Platelet Function Assessment .................................. ....................................... 25  
8.2.1.3  Serum Biomarkers for Fibrosis and Inflammation ................ ........................ 25  
8.2.1.4  Incidence of Variceal Bleeds .................................. ........................................ 26  
8.2.1.5  Safety Labs ................................................... ................................................. 26  
8.2.2  Description of Screenin g/Baseline Period ...................... ................................... 27  
8.2.3  Enrollment Confirmation and Procedures ........................ ................................. 28  
8.2.4  Description of Treatment Period ............................... ........................................ 29  
8.2.4.1  Day 1 ......................................................... ..................................................... 29  
8.2.4.2  Day 10 ........................................................ .................................................... 29  
8.2.4.3  Day 45 ........................................................ .................................................... 30  
8.2.4.4  Day 90 / Early withdrawal ..................................... ........................................ 30  
8.2.4.5  Follow-up ..................................................... .................................................. 31  
8.2.5  Potential Drug-induced Liver Injury ........................... ...................................... 31  
8.2.5.1  Criteria for Initiati ng Protocol for Potential DILI Cases ..... .......................... 31  
8.2.5.2  Protocol for Potential DILI Cases ............................. ..................................... 31  
9  SUBJECT DISCONTINUATION ....................................... ...................................... 33  
9.1  Subject Discontinua tion - General ............................. ............................................ 33  
9.2  Subject Discontinuati on - Protocol-specified Common Terminology  Criteria for 
Adverse Events (CTCAE) ........................................ ............................................. 34  
9.3  Procedures for Subject Discontinuation ........................ ........................................ 34  
9.4  Study or Site Termination ..................................... ................................................. 34  
10  ADVERSE EVENTS ................................................ ................................................. 35  
10.1  Definitions ................................................... .......................................................... 35  
10.1.1  Adverse Event Definitions ..................................... ........................................... 35  
10.1.2  Adverse Event Assess ment Definitions .......................... ................................... 37  
10.2  Collection, Recording and Re porting of Adverse Events ......... ............................. 38  
10.3  Study-Specific Guidance Perta ining to Adverse Events .......... ............................. 39  
10.3.1  Variceal Bleeding ............................................. .................................................. 39  
10.3.2  Cirrhosis Decompensation ...................................... ........................................... 40  
10.3.3  Clinical Bleeding Events ...................................... ............................................. 40  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 8 10.4  Subject or Study Discontinuati on Due to Adverse Event ......... ............................. 40  
10.5  Follow-up of Adverse Events ................................... ............................................. 41  
11  STATISTICAL METHODS AND DATA ANALYSIS ......................... ..................... 41  
11.1  Sample Size Determination ..................................... .............................................. 41  
11.2  Subject Population( s) for Analysis ............................ ............................................ 41  
11.3  Statistical Methods ........................................... ..................................................... 42  
11.4  Interim Analysis .............................................. ....................................................... 42  
12  STUDY MANAGEMENT AND DATA COLLECTION .......................... ................ 42  
12.1  Confidentiality ............................................... ........................................................ 42  
12.2  Source Documents .............................................. ................................................... 42  
12.3  Case Report Forms ............................................. ................................................... 42  
12.4  Records Retention ............................................. .................................................... 43  
13  STUDY MONITORING, AUDITING, AND INSPECTING .................... ............... 43  
13.1  Study Monitoring Plan ......................................... ................................................. 43  
14  ETHICAL CONSIDERATIONS ........................................ ....................................... 43  
14.1  Informed Consent .............................................. .................................................... 44  
14.2  Protocol Compliance ........................................... .................................................. 44  
14.3  Financial Disclosure .......................................... .................................................... 44  
14.4  Study Files ................................................... .......................................................... 45  
15  REFERENCES .................................................... ...................................................... 45  
16  SUMMARY OF CHANGES ............................................ ......................................... 46  
 
 
LIST OF TABLES 
Table 8.1-1  Schedule of Events ............................................ .................................................... 23  
 
 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 9 4 LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
Abbreviation Definition 
AE adverse event/experience AERD aspirin exacerbated respiratory disease 
AKI acute kidney injury 
ALT alanine aminotransferase ALP alkaline phosphatase 
aPTT activated partial thromboplastin time 
APRI aspartate aminotransferase/platelet ratio AST aspartate aminotransferase 
AUC area under the curve 
AUC-ROC area under the curve of t he receiver operator character istics 
BUN blood urea nitrogen 
C celsius 
CBC complete blood count 
CFR Code of Federal Regulations 
CKD chronic kidney disease cm centimeter 
C
max maximum concentration 
CRF Case Report Form CTCAE Common Terminology Criteria for Adverse Events 
D5W 5% dextrose in water 
DILI Drug-induced liver injury dL deciliter 
EGD esophagogastroduodenoscopy  
ET early termination EU European Union 
F fahrenheit 
FDA Food and Drug Administration FHVP free hepatic venous pressure 
GCP Good Clinical Practice 
GI gastrointestinal 
HBsAg hepatitis B s urface antigen 
HBV hepatitis B virus HCV hepatitis C virus 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 10 Abbreviation Definition 
Hg mercury 
HRS hepatorenal syndrome 
HSC hepatic stellate cells HVPG hepatic venous pressure gradient 
ICH International Conf erence on Harmonization  
IEC Independent Ethics Committee IMP investigational medicinal product 
IRB Institutional Review Board 
IV intravenous 
kPa kilopascal 
LSM Liver stiffness measurement MedDRA medical dictionary f or regulatory activities 
MELD model end stage liver disease 
mg milligram mL milliliter 
mm millimeter 
mm Hg millimeter mercury 
MRE Magnetic Resonance Elastography PT-INR Prothrombin time – int ernational normalized ratio 
RNA ribonucleic acid 
ROTEM rotational thromboelastometry  SAE serious adverse event 
SBP systolic blood pressure 
SCr serum creatinine TEG thromboelastography 
TIPS transjugular intrahepa tic portosystemic shunt 
T
max time to maximum concentration 
TPr thromboxane prostanoid receptor  
TxA 2 thromboxane A 2 
US United States of America 
USP United States Pharmacopeia 
VCTE Vibration Controlled T ransient Elastography 
WHVP wedged hepatic venous pressure 
 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 11 5 INTRODUCTION 
This study is to be performed in accordance with Good Clinical Practice (GCP), the ethical 
principles that have their origi n in the Declaration of Helsink i, Title 21 of the Code of Federal 
Regulations Parts 50, 56 and 312, and t he International Confere nce on Harmonization E6. 
5.1 Background Information 
Cirrhosis is a potentially life- threatening condition that occu rs when the liver is damaged by 
fibrotic scarring. Fibrosis can i mpair the flow of portal blood  through the hepatic sinusoids and 
result in hypertension in the por tal vasculature. One of the ma jor complications from portal 
hypertension is the development of gastrointestinal varices. Bl eeding due to varices specifically in 
the esophagus accounts for one third of the deaths related to p ortal hypertension. The median 
survival period in humans following diagnosis of cirrhosis is s ix years ( La Vecchia 1994 ; Pagliaro 
1994 ). Currently little effective therapy is commercially available  f o r  t r e a t m e n t  o f  p o r t a l  
hypertension.  
In the study of portal hypertension, there is key interest in m ediators such as thromboxane A2 
(TxA 2), F2-isoprostanes, nitric oxi de, and endothelin-1 as well as t he thromboxane receptor (TPr) 
which has TxA 2 and F2-isoprostanes as two of it s main ligands. F2-isoprostane s have been shown 
to mediate and promote fibrosis via TPr activation in hepatic s tellate cells (HSC) from rats treated 
with cirrhosis-inducing carbon te trachloride (Acq uaviva 2013). HSCs play a significant role in the 
progression of cirrhosis by increasing the amount of extracellu lar matrix in the hepatic 
parenchyma.   
In addition to the fibrotic proces ses, many of these same media tors have a more immediate effect 
on the blood flow through the hepatic sinusoids. TxA 2 serves as a vasoconstrictor , while nitric 
oxide vasodilates in the healt hy liver (Yokoyama  2005). However , in the cirrhotic liver, studies in 
rats have revealed an increase in the hepatic production of TxA 2 which would then further increase 
portal hypertension via vasocons triction (Graupera 2003; Rodrig uez-Vilarruplas 2012).  Also, the 
compensatory feedback between TxA 2 as a vasoconstrictor and nitr ic oxide as the inhibitory 
vasodilator seems to disappear i n the cirrhotic liver (Yokoyama  2005).            
Blockade of thromboxane-mediated signaling in the TPr has revea led an anti-fibrotic effect in two 
rat models of cirrhotic disease (Rosado 2013 ). Additionally, interrupting this signaling pathway 
lowered portal pressure suggesti ng a reduction in hepatic vascu lar resistance.    
Clinical trials utilizing antagonists of other potent vasoconst rictors of the hepatic portal system 
(e.g. endothelin-1) have been com pleted with little success, su ggesting that TxA 2 signaling may 
be of particular importance (T ripathi 2006). Therefore, the cur rent study is being conducted to 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 12 collect safety and efficacy data from the use of the TPr antago nist, ifetroban, in patients with portal 
hypertension. 
5.2 Stage of Development  
This is a Phase II exploratory study to determine the safety of  oral ifetroban compared to placebo 
in patients with portal hyperten sion. The efficacy of oral ifet roban compared to placebo in reducing 
portal pressure and liver fibro sis will also be explored. 
5.3 Patient Population 
Adult patients with liver cirrhosis, confirmed by liver biopsy,  laboratory features, and/or 
elastography findings will be c onsidered for study participatio n. Portal pressure s are measured by 
the hepatic venous pressure grad ient (HVPG) method during scree ning. A HVPG reading greater 
than 5 mm Hg defines portal hypertension, while higher HVPG val ues > 10 mm Hg suggest 
patients that are at a significant risk of developing gastroint estinal varices. This study will select 
patients with a baseline mean HVPG of > 8 mm Hg as they will ha ve significant disease 
progression to be candidates for the study of an effect to the investigational treatment.  Patients 
with baseline mean HVPG values over 18 mm Hg will be excluded a s a surgical intervention may 
be indicated at this severity of disease.     
5.4 Trial Rationale 
Antagonism of the TPr has shown be neficial results in preclinic al studies of cirrhosis with portal 
hypertension. The current standard of care for treatment of por tal hypertension focuses on 
management of symptoms, including mechanical hemostasis of vari ces, pharmacologic support 
with B-blockers and surgical relief of the increased portal pre ssure with the transjugular 
intrahepatic portosystemic shunt (TIPS) procedure. By antagoniz ing the TPr, administration of 
ifetroban may treat this condition at a more foundational level , allowing both short- and long-term 
relief of portal hypertension and c irrhosis through a reduction  in vasoconstricti on and fibrosis. 
The intervention will be adminis tered in both an intravenous an d an oral form. The initial dose of 
ifetroban is intravenous and a potential immediate effect due t o vasodilation will be studied; 
subsequently, oral dosing will c ontinue at home for 3 months du ring which time the disease will 
be further monitored.         
5.5 Risk-Benefit Assessment 
Clinical history with the use of ifetroban in patients with car diovascular disease or cardiac risk 
factors, and in patients with hepatorenal syndrome (HRS) or asp irin exacerbated respiratory 
disease (AERD) has not identifie d any major risks with ifetroba n use. Adverse events seen more 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 13 commonly in patients receiving ifetroban compared to those in p lacebo arms include bradycardia 
and gastrointestinal events. The need for coronary artery bypas s and coronary angioplasty 
procedures was also higher in the ifetroban treatment groups st udied in cardiovascular trials. The 
mechanism of action of ifetroban ( i.e. TPr antagonist resulting in inhibition of platelet aggregation ) 
suggests the potential for an in creased incidence of bleeding. The available clinical data have not 
demonstrated an increase in hemorrhagic events; however, subjec ts enrolled in ifetroban trials 
should be monitored for events such as spontaneous hemorrhage, decreased hemoglobin, and 
prolonged bleeding time.  Any hemorrhagic event occurring in th is study is reported as an adverse 
event as directed in Section 10.3.  Additionally, platelet func tion testing is performed according to 
Section 8.2.1.2.Ifetroban has not been investigated in patients  with portal hypertension, so no 
benefit is proven; however, as described above in 5.1 and 5.4, there is evidence that blocking the 
TPr may decrease portal hyperten sion via both acute and chronic  mechanisms.            
6 STUDY OBJECTIVES 
The exploratory objectives of t his study are to evaluate the fo llowing in cirrhotic patients with 
portal hypertension that are  treated with ifetroban:  
 Safety 
 Portal pressure 
 Serum liver enzymes 
 Surrogate markers of liver fibrosis and inflammation 
 Occurrence of variceal bleeds  
6.1 Study Endpoints 
The study objectives will be assessed utilizing the following e ndpoints; see 8.2.1  for details of the 
assessments:  
 To evaluate the safety of ifet roban treatment in this populatio n, the incidence and severity 
of adverse events will be compare d between the ifetroban and th e placebo groups.  
 To evaluate the effect of ifetroban treatment on portal pressur e in this population, the 
change from baseline in the mea n HVPG will be calculated at 15 minutes, 30 minutes and 
Day 90 following the completion of  the first investigational me dicinal product (IMP) dose 
and compared to placebo patients.     
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 14  To evaluate the effect of ifetroban treatment on serum liver en zymes in this population, the 
aspartate aminotransferase (AST)  and alanine aminotransferase ( ALT) values on Day 45 
and Day 90 will be compared to baseline for ifetroban and place bo patients.   
 To evaluate the effect of ifetroban treatment on liver fibrosis  and inflammation in this 
population, the change from baseline to Day 45 and Day 90 will be calculated for ifetroban 
and placebo patients in the following assessments: 
o Aspartate aminotransferase/platelet ratio (APRI) 
o Specified serum biomarkers 
 To evaluate the occurrence of v ariceal bleeds in this populatio n, the incidence and severity 
of any variceal bleeds will be documented.  
7 STUDY DESCRIPTION 
7.1 Study Design 
 Phase II, randomized, double-blind, and placebo-controlled pilo t study. 
 Thirty patients will be enrolled; twenty patients will be alloc ated to ifetroban and ten will 
receive placebo.   
 Each qualified subject will rema in in the study for 90 days.  E nrollment for the entire study 
is expected to take twelve months.  
 A schedule of assessments is summarized in Table 8.1-1 .  
7.2 Randomization and Blinding Conditions and Methods 
7.2.1 Randomization 
Randomization will be performed manually. The aim is to include  twenty patients treated with 
ifetroban and ten patients with placebo. There is no stratifica tion of patient sub-populations.  When 
the investigator confirms the eligibility of a subject and the intent to treat, he will advise the 
unblinded staff from his center to contact the unblinded sponso r representative. Email or phone 
correspondence is utilized and cal lers identify themselves with  respect to their unblinded role on 
the study. The unblinded sponsor  representative manually random izes the subject, using the 
allocation list created prior to the study start, and communica tes the assignment to the unblinded 
site personnel in writing (email  or fax). The written records w ill be maintained at the site and at 
the sponsor to document the assignment for each subject.     
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 15 7.2.2 Unblinding Conditions and Procedures 
Breaking the blind for a subjec t should be considered only when  knowledge of the treatment 
assignment is deemed essential by the subject’s physician for t he subject’s care. Given that there 
are no antidotes for ifetroban, unblinding is not likely to lea d to a change in treatment of the patient 
beyond holding or discontinuing the IMP. As such, unblinding sh ould be a rare occurrence. 
If time permits, and if signifi cant risk is not introduced to t he patient, the investigator will contact 
the medical monitor at the sponsor  to discuss the desire to unb lind the treatment assignment. If 
agreement is reached that unblinding should occur, the blinded clinical monitor will mediate 
contact between the investigat or and the unblinded sponsor cont act, as needed, to disclose the 
treatment assignment. All discus sions on this topic, including the treatment disclosure, if 
applicable, will be documented and filed in the study files.  
In emergency scenarios, the Investigator may contact the blinde d clinical monitor directly who 
will then mediate communication with the unblinded sponsor cont act.     
Any intentional or unintentiona l breaking of the blind at an in vestigative site must be reported to 
the Sponsor immediately.  
7.3 Drugs and Dosages 
7.3.1 Identification and Description of Test Agents 
7.3.1.1  Ifetroban Injection 
Ifetroban injection is available for investigational use only. Ifetroban injection is packaged as a 
clear, colorless to light yellow liquid in 5 mL glass vials, ea ch containing 50 mg ifetroban in a total 
volume of 5 mL (10 mg/mL). Ifetroban injection contains the fol lowing inactive ingredients: 
mono- and dibasic sodium phosphate , sodium chloride, and Steril e Water for Injection, United 
States Pharmacopeia (USP). 5% dextrose in water (D5W), which wi ll be supplied by each site, 
will be used as the diluent for this study. 
The investigational labels on t he ifetroban injection appear as  follows: 
 
   
 Ifetroban injection, 50 mg (10 mg/mL) 
Lot number: 1-FIN-1122    Volume: 5 mL  
Store at room temperature. Instructions: Use as directed. 
Caution: New Drug—Limited by Un ited States Law to Investigation al Use 
Cumberland Pharmaceuticals Inc., Nashville, TN 37203 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 16 7.3.1.2  Oral Ifetroban Capsules 
Oral ifetroban is supplied as a capsule dosage form (size # 1, white opaque) for oral administration. 
The formulation consists of ifetroban, mannitol, microcrystalli ne cellulose, crospovidone, 
magnesium oxide, colloidal silic on dioxide, and magnesium stear ate.  Capsules are filled into high 
density polyethylene bottles and sealed with screw-cap closures .  Capsules are only available at 
one strength of the sodium salt, i.e. 52.5 mg corresponding to a free-acid dose of 50 mg.  
7.3.1.3  Oral Placebo Capsules 
Matching placebo capsules consist  of microcrystalline cellulose , crospovidone, colloidal silicon 
dioxide, and magnesium stearate filled into size # 1, white opa que capsules. Capsules are filled 
into high density polyethylene bot tles and sealed with screw-ca p closures. 
The bottles of oral Ifetroban or placebo will contain the follo wing information on the label:  
 
      
Additionally, each individual bottle will be labelled with a un ique numeric code that identifies the 
contents to the unblinded sponsor representative.   
7.3.2 IMP Preparation and Dosing Instructions 
Personnel at the site must be identified and documented by the Investigator as blinded or unblinded 
staff. A site-specific written p rocess describing how the blind  will be maintained during the 
preparation, administration a nd dispensing of IMP should be uti lized. 
7.3.2.1  Ifetroban or Placebo Injection 
As described in 8.2.3, the ifetroban or placebo injection will be prepared by the unblinded 
pharmacy based on the “provision al eligibility confirmation” of  a new subject. If the subject is not 
ultimately confirmed as eligible, the prepared IMP will be disc arded by the pharmacist and the 
process documented.  PLACEBO OR IFETROBAN CAPSULES 50MG 
Quantity: 75 Capsules 
Instruction: Take capsules by mouth as directed. 
Store at controlled r oom temperature, 20oC – 25oC (68oF – 77oF) 
Caution: New Drug-Limited by Feder al law to investigational use  
Cumberland Pharmaceuticals Inc. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 17  Enrolled subjects are to receive an initial intra venous infusi on of IMP on Day 1, to be infused over 
15 minutes. The infusion is composed of 100 mL of 5% Dextrose i n sterile water (D5W) for 
subjects assigned to placebo, or 150 mg (15 mL) of ifetroban di luted in 85 mL of D5W for ifetroban 
subjects. The ifetroban infusion is formulated by aseptically t ransferring a total of 15 mL of 
ifetroban injection from three 50 mg vials to a 100 mL bag of D 5W after 15 mL of D5W are first 
removed and discarded. The 100 mL  is infused over 15 minutes us ing the site’s standard processes. 
A label with the following information is adhered to the infusi on bag by the unblinded pharmacist:  
 Placebo or 150 mg ifetroban injection  
 “Infuse intravenously over 15 minutes” 
 “Caution: New Drug—Limited by US Law to Investigational Use” 
Also, subject to the institution’ s labeling methods for investi gational medicine, it is suggested that 
the label also contain the following:  
 Subject identification number  
 Protocol number: CPI-IFE-005 
 Investigator Name  
Because ifetroban injection contains no bacteriostatic agents, vials are for single use only. Any 
unused portion of an ifetroban injection vial should be not be used for further dosing. All partially 
used vials should be retaine d for monitoring by the sponsor. 
Ifetroban infusion solutions should be infused as soon as pract ical after preparation, but no later 
than eight hours after preparation if left at room temperature.  Alternatively, ifetroban infusion bags 
may be stored for up to 24 hours if stored between 2 – 8 ºC. In fusion bags should be protected 
from freezing.    
7.3.2.2  Oral Ifetroban or Placebo   
Day 1 Dispensation 
According to the treatment assign ment, the unblinded pharmacist  receives individual bottle 
numbers from the unblin ded sponsor representative for dispensat ion to the corresponding subject. 
Whereas the IMP infusion is dispensed based on “provisional eli gibility confirmation” ( 7.3.2.1 ), 
oral IMP is only dispensed after eligibility is confirmed. Four  bottles of placebo or ifetroban, each 
with 75 capsules (total of 300 capsules), are dispensed at Day 1.    
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 18 The bottle identification numbers  do not disclose the contents of the bottle to unblinded staff.  
Therefore, for each dispensati on, the numbers are recorded in t he pharmacy records and also 
provided to the blinded treatment site staff for entry into the  case report form. The subject is 
directed not to throw away any empty bottles or unused capsules  and to bring all bottles with them 
to subsequent visits wit h the Investigator.    
Day 45 Dispensation 
At the Day 45 visit, any empty bottles are returned by the subj ects and two new bottles, in addition 
to unused or partially-used bottles dispensed at Day 1, are sen t home with the patient dispensed 
after bottle identifi cation numbers for the new bottles are pro vided to the pharmacist by the 
unblinded sponsor contact. An additional new bottle may be disp ensed in cases where the 
Investigator believes the quant ity may be necessary to complete  treatment through the final study 
visit. Bottle identification num bers for each dispensation are recorded in the unblinded pharmacy 
records. The subject is instruc ted to continue the same dosing regimen through Day 90.   
Dosing Instructions   
The subject is prescribed to begin taking their oral dose on Da y 2, the day following their 
intravenous dose. Ifetroban and placebo should be taken at leas t 30 minutes before a meal or 6 
hours after a meal. Therefore, i t is advisable to recommend the  subject dose themselves each day 
soon after waking up.   
All subjects are to take five capsules once daily throughout th e 90-day treatment period.  All 
capsules are taken in the same ep isode. In a double-blinded man ner, ifetroban subjects will take 
five capsules of 50 mg ifetroban daily; placebo subjects will t ake five capsules of matched placebo 
per day. 
7.3.3 Drug Accountability Procedures 
Ifetroban and placebo labeled for investigational use will be p rovided without charge by 
Cumberland Pharmaceuticals Inc. The investigator is required to  keep complete and accurate 
records of the receipt, dispensa tion, disposal and return of al l clinical trial drugs provided during 
the conduct of the study. Cumberland Pharmaceuticals will ensur e maintenance of complete and 
accurate records of the receipt, dispensation, disposal or retu rn of all trial drugs. 
Additional details regarding the monitoring of drug accountabil ity and patient compliance with at-
home dosing is covered in 8.2.4 .  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 19 7.4 Selection of Study Population 
Determination of study eligibility will be made by the Investig ator on the basis of the inclusion 
and exclusion criteria listed below. 
7.4.1 Inclusion Criteria 
To be considered eligible to participate in this study, a patie nt must meet the following inclusions 
criteria: 
1) Adults with cirrhosis, defined a s meeting at least one of the f ollowing:   
a) Histopathological diagnos is of liver cirrhosis 
b) Historical HVPG value > 7 mm Hg 
c) Liver stiffness measurement (LSM) greater than 
 15 kPa, if measured by Vibration C ontrolled Transient Elastogra phy (VCTE), or 
 6.7 kPa, if measured by Magnetic Re sonance Elastography (MRE) w ith at least one of 
the two following criteria:  
i) Evidence of splenomegaly or collateral portal-venous anastomose s on imaging or 
endoscopy without portal vein thrombosis 
ii) Platelet count below 150 x 103/µL and AST value greater than ALT  
 
2) At least two stable baseline va lues for each of the following v ariables: AST, ALT, ALP and 
bilirubin.  One value will be from the study screening period, and the other value(s) taken 
between 15 and 90 days prior to the  screening labs.   Stable is  defined as values having a 
difference < 40 U/L for AST and ALT, < 60 U/L for ALP and < 3.0  mg/dL for t otal serum 
bilirubin  
3) Baseline mean HVPG measurement > 8 and < 18 mm Hg 
7.4.2 Exclusion Criteria 
To be considered eligible to participate in this study, a patie nt must not meet any of the following 
exclusion criteria: 
1. Be less than 18 years of age  or greater than 70 years of age. 
2. Be pregnant, nursing, or pla nning to become pregnant. 
3. Have portal or splenic vein thrombosis.  Patients with portal o r splenic vein thrombosis in 
their history may participate if  there is more recent confirmat ion that there is no occlusion 
or that no thrombosis  is detectable.    
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 20 4. Previous transjugular intrahepa tic shunt (TIPS) or portocaval s hunt. 
5. Variceal or other gast rointestinal bleed i n the two months prio r to enrollment. 
6. Current or scheduled hemodialysis. 
7. Most recent Child-Pugh Score >  12, within 30 days of enrollment . 
8. Most recent MELD-Na score >  20, within 30 days of enrollment.  
9. Current acute kidney injury, chronic kidney disease, or most-re cent baseline serum 
creatinine > 2.0 mg/dL.  
10. Active alcohol consumption (grea ter than an average of two drin ks per day). 
11. Active hepatitis B virus (HBV) or hepatitis C (HCV) infection; current treatment, except 
suppression treatment for HBV , or  plans to initiate treatment f or HBV or HCV during study 
involvement; or eradication of  HCV within previous 3 months.  
12. Platelet count < 60 x 103/µL 
13. Confirmed or suspected diagnoses of Vitamin A toxicity, extrame dullary hematopoiesis, or 
Budd Chiari Syndrome. 
14. Use of endothelin receptor antagonists, somatostatin analogues or prostanoids in the last 
seven days or planned use during the study. 
15. Myocardial infarction in the  90 days prior to enrollment. 
16. History of bleeding diathesis OR  any risk factors for bleeding based on patient or familial 
history, other than cirrhosis and its sequelae, or use of antic oagulant or antiplatelet drugs, 
including aspirin, in the las t 14 days or planned use during th e study. 
17. History of allergy or hyperse nsitivity to i fetroban. 
18. Have taken investigational dr ugs within 30 days before IMP admi nistration. 
19. Inability to understand the require ments of the study, spoken E nglish, or the need to abide 
by the study restrictions and to ret urn for the required treatm ents and assessments. 
20. Be otherwise unsuitable for th e study, in the opinion of the in vestigator. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 21 7.5 Prior and Concomitant Therapy 
Patients may enter the study while on a beta blocker but the pa tient must be on a stable dose for at 
least 30 days prior to enrollment, and the dose may not be alte red or stopped during the Treatment 
Period. Beta-blocker-naïve patients may not initiate beta block er therapy during the Treatment 
Period. 
Drugs from the statin class are allowed if the patient has been  on a stable dose for three months 
and will continue on that dose throughout the study.   
7.5.1 Excluded Medications/Procedures/Therapy 
Some concomitant medications are prohibited during study involv ement as detailed below. As 
applicable, some medications must undergo a sufficient wash-out  period before a subject can begin 
study treatment. 
The following drugs are not allowe d to be taken between Day -14  and the end of study treatment:  
 Aspirin, other anti-platelet  drugs, and anticoagulants  
The following drugs are not allowe d to be taken between Day -7 and the end of study treatment: 
 Endothelin receptor antagonists, somatostatin analogues and pro stanoids 
 Drugs from the nitrate class 
 Treatment protocols for HBV or HCV 
7.5.2 Dietary and Fasting Requirements 
Food effect studies have demonstr ated that high fat, protein or  carbohydrate meals all have a 
similar effect of decreasing the maximum serum concentration (C max) (average of 80-90%), 
prolonging the time of maximum plasma concentration (T max) (8-12 fold), and decreasing the area 
under the concentration time-curve s from time zero to infinity (AUC 0-∞) of oral ifetroban  (average 
of 25-35%) compared to the fasting state.  
For this study, ifetroban and pl acebo for ifetroban capsule sho uld be taken at least 30 minutes 
before a meal or six hou rs after a meal.   
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_24Jul2017  Page 22 8 EXPERIMENTAL PROCEDURES 
8.1 Overview – Schedule of Time and Events 
The study consists of a 14-day screening period, a 90-day treat ment period where blinded 
investigational treatment is giv en as an initial intravenous (I V) dose, then daily doses of oral IMP. 
A 7-day follow-up completes the study. The schedule of events f or the study, including allowable 
time windows appears in Table 8.1-1  below.  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharm aceuticals Inc. Ifetroban Injection and Capsules 
CPI_IFE-005; Protocol Amendment 02_21Jun2017  Page 23 Table 8.1-1 Schedule of Events 
Study Phase Screening Baseline Day 1 Day 10 Day 45 Day 90 /  
Early Term Follow-up 
Allowable Windows Day -14 
to Hour 0 Hour -6 
to Hour 0 + / -  3  
days +/- 5 
days From -5 to 
+0 days (Day 85-90)6 to 8 days 
following Day 90/ET visi
t
Demographic Data X       
Medical History X  
Review of Inclusion/Exclusion X X      
Pregnancy Tes t X   
Physical Exam X X X X
Hepatic Venous Pressure 
Gradient Measurements  X  - 15 minutes following start of IMP  
- 30 minutes following start of IMP       X   
Serum Biomarker Sample 
Collection X    X X  
Safety Labs X* X X X
Platelet Function Testing X   X Repeat testing in cases of clinical 
bleeding events ( Section 8.2.1.2 )
HBV and/or HCV testing, 
if needed  X       
VCTE, if needed  X 
Vital Signs  X after IV IMP completion X X X  
IMP dosing – intravenous  Start of IV dose defines Hour 0  
IMP dosing - oral   Once daily oral IMP dosing begins on Study Day 2 and continues 
through Day 90 
Review of Drug 
Accountability    X X X  
Con Med monitoring Continual  
Adverse Event monitoring   Continual Phone Call 
* Per Inclusion Criterion #2, if historical ALT, AST, ALKP, and  bilirubin are not available from between 15- and 90-days prior  to the safety labs drawn duri ng screening, an initial set of l abs, reporting 
ALT, AST, ALKP, and bilirubin, w ill be require d by the study pr ior to screening but following the subject’s consent.  In such a case, full safety labs per 8.2.1.5  will be assessed 15-90 days later during 
the 14-day screening window shown above.
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 24 8.2 Measurements and Evaluations 
8.2.1 Description of Key Study Assessments 
8.2.1.1  Hepatic Venous Pressure Gradient (HVPG) Measurement  
A recorder capable of generating permanent tracings (paper and/ or electronic) must be used for 
this study. Following standard medical process regarding sedati on, aseptic preparation of the 
venous access site and catheter care, initial venous access is established through a route and method 
chosen by the Investigator or qualified designee. Ultimately, a  balloon-tipped catheter is placed in 
the main right hepatic vein unde r fluoroscopic guidance until t he tip is approximately 5 cm from 
the vena cava. The succeeding steps are then followed to record  the hepatic venous pressure 
gradient:  
1. The balloon is inflated and dye is injected to confirm complete  occlusion of the catheterized 
vein. Dye that circumvents the balloon or is shunted to other v enous return will require the 
catheter to be repositioned.   
2. The inflated catheter is left in place for approximately 45 sec onds while pressure is 
recorded and stabilized [wedge d hepatic venous pressure (WHVP)] . 
3. The balloon is completely deflated and the catheter is retrieve d proximally until the tip is 
approximately 2 cm fro m the vena cava.  
4. Pressure recordings continue for approximately 45 seconds [free  hepatic venous pressure 
(FHVP)]. 
5. After 1 minute, the catheter is advanced distally to its origin al position and the balloon 
inflated.  
6. Steps 2-4 are repeated at least two additional times.   
7. The hepatic venous pressure gradient is measured as the differe nce between the stable 
WHVP reading and the subsequent stable FHVP reading. At the Bas eline and Day 90 time 
points, pressure gradients will be recorded until three HVPG va lues are all within 1 mm 
Hg of each other. .  For the +15 and +30 minute recordings, the re will not be sufficient time 
to repeat more than three readi ngs, so the initial three indivi dual HVPG values will be 
accepted.   
The three  valid HVPG values, plus the mean, are recorded in th e study case report form for each 
time point.   
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 25 8.2.1.2  Platelet Function Assessment 
Platelet function will be measured during screening and at Day 10 by rotational 
thromboelastometry (ROTEM) in study centers that have the abili ty to perform ROTEM.  In other 
centers, thromboelastography (TEG ) will be utilized for the sam e purpose.  A citrated blood sample 
is drawn from all patients and the center’s laboratory standard  procedures are followed.  At a 
minimum, the maximum amplitude ( or maximum clot firmness) of th e clot profile is measured to 
assess platelet function; however , other values reflecting clot ting time, clot formation time, 
fibrinolysis, etc. w ill be collected in the case report.  
During the treatment or follow-up period, in any subject that e xhibits a clinical bleed, as directed 
in protocol Section 10.3, a repeat ROTEM or TEG analysis will b e performed at the initial onset 
of the bleeding episode, preferably prior to any associated tre atment intervention.  The same 
technology (ROTEM or TEG) that was  employed in the screening pr ocess will be used in cases of 
bleeding during the treatme nt phase of the study.       
8.2.1.3  Serum Biomarkers for Fibrosis and Inflammation 
Serum will be collected from blood draws at Baseline, Day 45 an d Day 90/Early-termination for 
measurement at a central laborat ory of specialized biomarkers o f hepatic fibrosis and 
inflammation. Approximately 10 mL  of whole blood will be drawn at each time point.  
Comparative levels of many variou s cytokines like the interleuk ins, transforming growth factors, 
chemokines, and others have been correlated with the extent of fibrosis and inflammation 
confirmed on liver biopsy (Deng 2015). Therefore, the levels of  key biomarkers may assist in the 
grading of liver disease or mon itoring of treatment progress an d avoid the risks and more-intensive 
effort behind liver biopsies. Additionally, there is evidence t hat other biomarkers may predict a 
patient’s HVPG and provide information about the presence or pr obability for varices without 
performing an esophagogastroduodenoscopy (EGD) (Buck 2014). Dat a showed that 86% of 
cirrhosis patients with HVPG below 12 mm Hg could be correctly identified without EGD.       
Details about the sample prepara tion are detailed in the labora tory manual.   
Additionally, the platelet count and AST results from the Safet y Labs (8.2.1.4) at Baseline, Day 45 
and Day 90 are used to calculate the Aspartate Aminotransferase /Platelet Ratio (APRI). The APRI 
is easily calculated from readily-available lab parameters, yet  is a good estimator of hepatic 
fibrosis. In a prospective study, the ability of the APRI to ac curately score fibrosis in HVC patients 
compared to liver biopsy was deemed good to excellent with and area under the curve of the 
receiver operator ch aracteristics (AUC-R OC) of 0.889 (Snyder 20 06).        
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 26 8.2.1.4  Incidence of Variceal Bleeds 
The occurrence and details of any variceal bleeds during the tr eatment period will be captured in 
a dedicated module of the Case Report Form (CRF) and occurrence s will be reported as endpoints 
in the study results. If the bleed meets the criteria of an adv erse event, it will also be captured as 
an adverse event according to standard GCP reporting processes.    
Variceal bleeding is defined for  this study as the presence of either reported or witnessed 
hematemesis, melenemesis, melena , or bright red blood per rectu m and a concomitant drop in 
hemoglobin of 1 gm/dL compare d to baseline and no other source of bleeding.   
Additional diagnostics, including upper gastrointestinal endosc opy, will not be ordered by the 
study protocol; however, results from any standard of care proc edures should be captured in the 
study records.  
Treatment for any bleeding will be ordered at the Investigator’ s discretion according to standard 
of care.   
8.2.1.5  Safety Labs 
Blood sample collection for safety laboratory assessments will be performed within protocol-
specified time periods and according to the site’s standard pra ctices for drawing and processing 
samples. The following analytes are measured by the site’s loca l laboratory and evaluated by the 
investigator with respect to r eference ranges provided by that lab: 
 Hematology and coagulation 
o Complete blood count (CBC) with differential 
 Total white blood cell count 
 absolute counts for  
 neutrophils 
 lymphocytes 
 monocytes 
 eosinophils 
 basophils 
 platelet count 
 hematocrit 
 hemoglobin 
o PT-INR (International Normalize d Ratio of Prothrombin Time) 
o aPTT (activated Partial Thromboplastin Time) 
 Clinical biochemistry with electrolytes 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 27 o Sodium 
o Potassium 
o Chloride 
o Total carbon dioxide 
o Glucose 
o Blood urea nitrogen (BUN) 
o Serum creatinine (SCr)  
o Total bilirubin 
o Albumin 
o Total protein 
o Aspartate aminotransferase (AST) 
o Alanine aminotransferase (ALT) 
o Alkaline phosphatase (ALP) 
8.2.2 Description of Screening/Baseline Period 
Before the initiation of study-sp ecific screening assessments, the patient or l egal authorized 
representative must be given a c omplete explanation of the purp ose and evaluations of the study.  
Subsequently, the patient or leg al authorized representative mu st sign and receive a copy of an 
Informed Consent Form that was approved by the center’s governi ng Institutional Review Board 
(IRB). Once informed consent has been obtained, the eligibility  of the patient to participate in this 
study will be determined by the Investigator on the basis of th e inclusion and exclusion criteria. 
Screening/Baseline Period assessments will also be performed ac cording to the protocol to 
determine eligibility. Only elig ible patients will be randomize d to receive IMP.  
During the Screening/Baseline Period, the following evaluations  will be performed to determine 
the patient’s eligibility for this study and document their bas eline disease state; allowable time 
windows are described in Table 8.1-1 : 
 Demographic data  
 Review and documentation of medi cal history. Subjects must be a sked about patient or 
familial history of bleeding diat hesis and any known risk facto rs for bleeding.  Resolved 
diseases or past procedures that are not significant to the dis ease under study should be 
captured if they occurred in the previous five years. Other his tory should be captured 
regardless of time reference.   
 A serum or urine pregnancy test will be performed on all women of child-bearing potential. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 28  A baseline physical examination w ill be performed for all signi ficant body systems.    
 Safety labs will be drawn and processed according to standard l ocal processes. Analytes to 
be measured are listed above in 8.2.1.4 .  Per inclusion criterion #2 (See Section 7.4.1 ), 
historical lab values for ALT, A ST, ALKP and bilirubin are requ ired from between 15 and 
90 days prior to the safety lab values drawn during screening f or comparison and 
confirmation of disease-state stability.  If no such lab values  a r e  a v a i l a b l e  t o  t h e  
Investigator, an initial panel will be drawn following the obta ining of subject consent, and 
the screening assessments, including a full safety lab panel (S ee Section 8.2.1.5 ) will be 
performed 15 to 90 days later, with in the defined screening per iod. 
 Additional serum will be collected for submission to the centra l lab for biomarker analysis 
as per the labor atory manual. 
 Active HBV and HCV must be ruled out prior to enrollment.  If t he patient’s HBV status 
is unknown, a Hepatitis B surface antigen (HBsAg) test will be performed.  If the patient’s 
HCV status is unknown, an HCV antibody test and/or, if needed, an HCV RNA test will be 
performed.    
 Baseline HVPG measurements are p erformed within t he 6 hours pri or to first IMP 
administration. However, as detailed in 8.2.3  below, this screening measurement will likely 
be performed immedia tely prior to IMP a dministration.   
 Baseline vital signs are taken i n the six hours prior to first IMP treatment: heart rate; 
respiration rate; body temperat ure; and indirect blood pressure .  
 If the subject has been diagnos ed with cirrhosis, but by a meth od other than those listed in 
inclusion criterion #1 (See Section 7.4.1 ), a VCTE will be performed to confirm a diagnosis 
of cirrhosis as defi ned in this protocol.   
8.2.3 Enrollment Confirmation and Procedures 
Because the final determination of subject eligibility is typic ally made after the baseline HVPG 
measurements which are immediately prior to the pending adminis tration of the first dose of IMP, 
the ifetroban or placebo injecti on needs to be prepared before complete eligibility is confirmed to 
allow for pharmacy preparation t ime. The Investigator will orde r the preparation of IMP injection 
based on the “provisional eligib ility confirmation” of a new su bject. The unblinded pharmacist 
will obtain the treatment assignment directly from the unblinde d sponsor representative at that 
time and prepare the infusi on per the instructions in 7.3.2.1 . If the subject is confirmed as eligible 
following the baseline HVPG asse ssment (i.e., mean HVPG > 8 mm Hg and < 18 mm Hg), the 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 29 infusion will continue as planned. If the subject does not meet  the HVPG requirement, they are 
considered a screen failed subjec t and their prepared infusion is discarded by the pharmacy and 
the process documented. 
8.2.4 Description of Treatment Period  
8.2.4.1  Day 1 
Hour 0 of the treatment period is  defined as the time when the intravenous infusion of IMP is first 
initiated. According to the site’s standard procedures, the 100  mL infusion volume will be 
administered over a 15-minute pe riod. As soon as allowable afte r the completion of the infusion, 
an assessment of the mean HVPG will be made according to the pr ocedure detailed in 8.2.1.1 . 
Additional assessments will be initiated at both 15 and 30 minu tes following the start of the IMP 
infusion.    
The subject will be dispensed a  quantity of 300 IMP capsules (4  bottles of 75 cap sules each) with 
instructions to begin a daily dose of 5 capsules (total 250 mg ifetroban or placebo) on the morning 
following the infusion. Drug administration at home should gene rally occur in the morning, but, if 
this does not happen on a given day, the dose should still be g iven at a later point during that day 
so that no dose is missed. All fi ve capsules are taken in the s ame episode.  Subjects are instructed 
to note any missed days of oral IMP and report those to study s taff.  Missed doses are not to be 
taken on a subsequent day.   
Enrolled subjects will be trained on how to identify petechial,  ecchymosis, and other signs of 
bleeding and they will be directed to discontinue further study  medication and contact the 
Investigator immed iately to report an y such symptoms.    
8.2.4.2  Day 10 
Subject will have a clinic visit on Day 10 (+/- 3 days) for a s afety follow-up evaluation. The visit 
will consist of a physical examination, including inspection fo r any symptoms of platelet 
dysfunction, vital sign measuremen t, and local lab assessment o f safety labs, including a platelet 
function assessment by ROTEM or TEG . Consistent with the entire  treatment period, changes in 
concomitant medications and any spo ntaneously-reported adverse events will be recorded.       
The subject must bring all bottles of IMP to the visit. The bli nded study coordinator performs a 
drug compliance evaluation and cal culates the percentage of com pliance based on the amount of 
capsules missing since the Day 1 dispensation. If compliance is  not 100%, the subject is re-
educated on the proper dosing regimen and the importance of bei ng fully compliant with study 
drug administration. A plan to follow-up additionally with the subject (e.g., by phone or other 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 30 communications) may be devised.  If the Investigator has any co ncern over the subject being able 
to maintain a drug compliance between 90% and 110%, the Investi gator will discuss continued 
study participation or  possible study withdr awal with the subje ct.    
8.2.4.3  Day 45 
A t  D a y  4 5  ( + / -  5  d a y s ) ,  a n  i n t e r i m  t r e a t m e n t - p e r i o d  v i s i t  i s  p e r f o r m e d  f o r  t h e  s t a n d a r d  s a f e t y  
evaluations (physical exam includ ing inspection of symptoms of platelet dysfunction, vital signs, 
and safety labs) and serum is collected and prepared for centra l laboratory submission for 
biomarker analysis. Additionally, the subject is directed to br ing the drug bottle(s) dispensed on 
Day 1 to the visit along with any unused capsules. Full drug ac countability is performed by the 
study staff, compliance is calculated, and any treatment compli ance issues are discussed between 
the Investigator and t he subject. If the Investigator has any c oncern over the subject being able to 
maintain a drug compliance between 90% and 110%, the Investigat or will discuss continued study 
participation or possible study withdrawal with the subject. Co mpliance is recorded in the CRF so 
values outside of the allowable 90 to 110% range are not record ed separately as protocol deviations 
in the CRF.       
Unless the subject withdraws fro m the study voluntarily or unde r direction by the Investigator, the 
subject is dispensed 150 additional IMP capsules with instructi ons to continue treatment.  Two 
bottles are sent home with the  subject in addition to any capsu les that were brought  by the subject 
to the Day 45 visit.   
In total, between the Day 1 and Day 45 Visits, each subject wil l be dispensed six bottles of 75 
capsules each.      
8.2.4.4  Day 90 / Early withdrawal  
The subject is directed to take the final oral dose of IMP at h ome on the day prior to their scheduled 
Day 90 Visit. All drug bottles a nd unused medication is brought  to the visit by the patient. Safety 
assessments (physical exam includ ing inspection of symptoms of platelet dysfuncti on, vital signs, 
and safety labs) are performed i n addition to the collection an d processing of serum for central 
analysis of biomarkers. The subj ect is again prep ared for hepat ic vein pressure measurements and 
HVPG measurements are recorded during the visit. Finally, compl ete drug accountability is 
performed and compliance calcu lated by the site staff.       
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 31 8.2.4.5  Follow-up 
A phone call is made by the study staff between 6 and 8 days fo llowing the Day 90/Early 
termination visit.  The subject i s asked about their medical st atus to assess for any spontaneously 
reported adverse events.   
8.2.5 Potential Drug-induced Liver Injury 
Subjects in this study are enroll ed with confirmed pre-existing  hepatic disease; therefore, published 
guidelines ( http://www.fda.gov/downloads/D rugs/.../Guidances/UCM174090.pdf ) for monitoring 
potential drug-induced liver inj ury (DILI) are available but do  not apply to the same degree.  
A modified protocol is followed when patients in the treatment or follow-up phases show evidence 
of possible DILI and need to be m onitored or have their study t reatment modified accordingly.   
8.2.5.1  Criteria for Initiating Protocol for Potential DILI Cases  
Any subject meeting any one of the  following criteria during th e treatment or follow-up phase 
will enter the protocol (See Section 8.2.5.2 below) for potenti al DILI cases:  
 An elevation of ALT or AST great er than 2 X the baseline value for that patient 
 An elevation of total bilirubi n greater than 1.5 X the baseline  value for that patient 
 Any increase in bilirubin seen i n conjunction with suspect hype rsensitivity signs or 
symptoms such as fever, rash, e osinophilia, nausea, vomiting, o r right upper quadrant 
pain mandates that the subject e nter the monito ring protocol, b ut also discontinue study 
drug immediately .    
8.2.5.2  Protocol for Potential DILI Cases 
All assessments made during the  monitoring of potential DILI ca ses will be captured in the CRF.   
Initial Evaluation 
Any subject that meets a criterion in Section 8.2.5.1 should ha ve liver enzymes and bilirubin levels 
repeated within 48 hours to conf irm the abnormalities and detec t if they are increasing or 
decreasing.  At that unscheduled  visit, the following assessmen ts will be performed and additional 
information collected: 
 Physical Exam with detailed assessment of symptoms 
 History of concomitant drug use  (including nonprescription medi cations and 
supplements), alcohol use, rec reational drug use, and special d iets. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 32  History of exposure to envir onmental chemical agents 
A diagnostic plan should be formulated and initiated by the Inv estigator, if appropriate based on 
history, physical exam findings and laboratory results, to rule  out additional poten tial causes of 
liver disease such as acute viral hepatitis types A, B, C, D, a nd E; autoimmune or alcoholic 
hepatitis; NASH; hypoxic/ischemic  hepatopathy; and biliary trac t disease.   
Monitoring 
At a minimum, liver enzyme and serum bilirubin testing should b e performed initially 2-3 times 
weekly until abnormalities stabi lize or the trial drug has been  discontinued and the subject is 
asymptomatic.  The scope and f requency of monitoring can then b e modified as appropriate.    
 
Decision to Stop Study Drug 
There is no strict guidance on when to stop study drug in a pat ient with pre-existing liver disease 
that is demonstrating some po ssible signs of drug-induced liver  injury.  Section IV .A.5 of the 
following guidance may be used f or reference and assistance: 
http://www.fda.gov/downloads/D rugs/.../Guidances/UCM174090.pdf   
 
The Medical Monitor should be con sulted as well in the decision  to continue or dis continue study 
drug.  
  
The decision to discontinue or temporarily interrupt study drug  treatment should generally be 
based on the following factors:  
 Stability or directi onal changes of ALT, AST, and bilirubin  
 Elapsed time during which values h ave remained higher than base line 
 The degree to which the baseline ALT, AST and bilirubin were hi gh relative to the upper 
limit of normal 
Please note that Section 8.2.5.1  directs the study drug to be stopped for cases of elevated bil irubin 
with concurrent symptoms such a s fever, rash, eosinophilia, nau sea, vomiting, or right upper 
quadrant pain.  
 
Follow-up 
All trial subjects s howing possible DILI should be followed unt il all abnormalities return to normal 
or to the expected baseline stat e given the pre-existing liver disease.   
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 33 9 SUBJECT DISCONTINUATION  
9.1 Subject Discontinuation - General  
Subjects will be encouraged to complete the study; however, the y may voluntarily withdraw at any 
time and for any reason. The Investigator will describe in the CRF the reason for the subject’s 
choice to discontinue.   
A subject may be removed from the study for the following reaso ns; in each case, the decision to 
discontinue should be confirme d following consultation between the Investigator and Sponsor: 
 Adverse event (AE): If a subject experiences an AE for which co ntinued study participation 
presents an unacceptable consequence or risk to the subject, th e subject may be 
discontinued under the Investig ator’s judgement. See also Section 9.2 . 
 Subject non-compliance: A subject ’s past, current, or anticipat ed inability to comply with 
study visits, clinical trial med ication or other processes requ ired by the protocol may lead 
to the decision to discontinue the subject from the study. The subject’s compliance in taking 
oral medication at home should be  within 90 and 110% at all vis its.    
 Enrollment violation: If it is realized after the initiation of  investigational treatment (or 
placebo) that a subject did not meet all eligibility requiremen ts, the Sponsor and 
Investigator will discuss whether it is safe, ethical, and scie ntifically sound to keep the 
subject in the study or to  discontinue the subject.   
 Concurrent Treatment: If a subject initiates a procedure or med ication that may interfere 
with their study conduct or for w hich study invo lvement may pos e a significant risk to the 
prescribed therapy, the subject may be discontinued. This also includes the use of therapies 
restricted by the protocol in Section 7.5 .     
 TIPS or shunt procedure duri ng the treatment period.  
 Liver transplant during t he treatment period.   
 Other reasons: Following discussion between the Sponsor and Inv estigator, subjects may 
be discontinued from the study for  reasons other than those lis ted above. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 34 9.2 Subject Discontinuation - Protocol-specified Common Terminology  
Criteria for Adverse Events (CTCAE) 
Subjects encountering adverse ev ents meeting either of the crit eria below will be discontinued 
from study drug but continued to be monitored for safety.  The Investigator will plan to remain 
blinded and consult with the sponsor’s Medical Monitor and a de cision will be made and 
documented regarding continued patient monitoring and criteria under which study drug would be 
re-initiated or additional effi cacy assessments would be perfor med.    
 Any grade 4 or higher adverse event defined by CTCAE (See Section 10.1.2  for guidance) 
 Any grade 3 adverse event that is classified by the Investigato r as possibly or probably 
related to study drug 
See also Section 10.4  regarding the unblinded review of safety data if multiple subj ects have 
significant AEs.   
9.3 Procedures for Subject Discontinuation 
If a subject is permanently withdr awn from study drug prior to completion of the full treatment 
period, a Day 90 visit, as descri bed above should be performed if the subject consents and there is 
no additional risk to the patient by performing the assessments . Following the visit, reasonable 
efforts should be made to monitor the subjec t for AEs, as appro priate.  
Subjects that are discontinued may be replaced, as needed. The decision will be made on a case-
by-case basis by the study sponsor.   
9.4 Study or Site Termination 
If conditions arise during the study that indicate that the stu dy should be halted or that the study 
center should be termin ated, this action may be taken after app ropriate consultation among the 
Sponsor, Investigator, Medical Monitor, and Study Monitor.   
Conditions that may warrant ter mination of the study include, b ut are not limited to, the following: 
 The discovery of an unexpected, serious, or unacceptable risk t o the subjects enrolled in 
the study 
 A decision on the part of the Sponsor to suspend or discontinue  testing, evaluation, or 
development of the product 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 35  See also  Section 10.4  regarding enrollment t ermination due to AEs. 
A study conducted at a single study site or a single study site  in a multicenter study may also 
warrant termination under the following conditions: 
 Failure of the Investigator to enr oll subjects in to the study a t an acceptable rate 
 Failure of the Investigator to comply with pertinent regulation s of appropriate regulatory 
authorities 
 Submission of knowingly false information from the research fac ility to the Sponsor, Study 
Monitor, or appropriate  regulatory authority 
 Insufficient adherence to  protocol requirements 
Study termination and follow-up will be performed in compliance  with the conditions set forth in 
the International Conference on Harmonization (ICH) sixth effic acy publication (E6) on Good 
Clinical Practice, S ection 4.12, ICH E6 4.13, ICH E6 5.20, and ICH E6 5.21. 
10 ADVERSE EVENTS 
Information about AEs, whether spontaneously reported by the su bject, discovered by the 
Investigator by questioning/revi ew of diary records or detected  through physical examination, 
laboratory test or other means, will be collected and recorded on the adverse event form and 
followed-up as appropriate. Info rmation about serious adverse e vents should be reported to the 
Sponsor within 24 hours of obtaini ng knowledge of the event.  
10.1 Definitions 
10.1.1  Adverse Event Definitions 
Adverse events are defined according to ICH Harmonized Triparti te Guideline E2A. 
Adverse event (AE)  
Any untoward medical occurrence in  a patient or clinical trial subject administered a trial product 
whether it has a causal relati onship with the s tudy treatment o r not.  
An adverse event can therefore be any unfavorable and unintende d sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporall y asso ciat ed w ith the use o f a 
medicinal product, whether or not c onsidered related to the med icinal product. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 36 The following are not considered an AE: 
 Pre-planned procedure (documente d as concomitant illness on the  CRF at screening) unless 
the condition for which the procedure was planned has worsened from the first trial related 
activity after the subject has si gned the informed consent form . 
 Pre-existing conditions found duri ng and as a result of screeni ng procedures. 
Serious adverse event (SAE)  
An AE that meets any of the following criteria:  
 results in death  
 is immediately life-threatening (t his refers to an event in whi ch the subject was at risk of 
death at the time of the event; it does not refer to an event t hat hypothetically might have 
caused death if it was more severe)  
 requires in-patient hospitaliza tion or prolongatio n of existing  hospitalization 
 results in persistent or signi ficant disability or incapacity 
 is a congenital anom aly or birth defect 
 is judged medically important in the opinion of the Investigato r (this refers to an event that 
may not be immediately life-threatening or result in death or h ospitalization, but may 
jeopardize the subject or may req uire intervention to prevent o ne of the other outcomes 
listed. 
Non-serious adverse event  
Any adverse event that does not  meet the definition of an SAE. 
Unexpected adverse event 
An adverse event or suspected adverse reaction is considered "u nexpected" if it is not listed in the 
investigator brochure or is not listed at the specificity or se verity that has been observed.  
"Unexpected," as used in this d efinition, also refers to advers e events or suspected adverse 
reactions that are mentioned in the investigator brochure as oc curring with a class of drugs or as 
anticipated from the pharmacologi cal properties of the drug, bu t are not specifically mentioned as 
occurring with the particular  drug under investigation. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 37 10.1.2  Adverse Event Assessment Definitions 
Anticipated 
Anticipated events include known consequences of an underlying disease or the condition under 
investigation, events anticipat ed from any background regimen, events common in the study 
population, or re-emergence or worsening of a condition relativ e to pretreatment baseline. 
Severity 
The reported event terms and severity grading of each event rep orted in this study adhere to the 
Common Terminology Criteria for Adverse Events (CTCAE) grading criteria, which is 
coordinated by the National Cancer Institute of the National In stitutes of Health. 
Resources including quick refere nces, governance documents and data files of adv erse events can 
be found here: http://evs.nci  nci.nih.gov/ftp1/CTCAE/About.html   
The Investigator, with  support from the st udy monitor, will rep ort adverse events using the lowest 
level terms, as identified by the Medical Dictionary for Regula tory Activities (MedDRA) 
http://www.meddra.org/ , whenever possible.   
The severity of each event adhere s to the severity grades estab lished by CTCAE: 
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagn ostic observations only; 
intervention not indicated.  
Grade 2  Moderate; minimal, local  or noninvasive intervention i ndicated; limiting age-
appropriate instrumental ac tivities of daily living.   
Grade 3  Severe or medically significant but not immediately li fe-threatening; 
hospitalization or prolongation of  hospitalization indicated; d isabling; limiting self-
care activities of daily living.  
Grade 4  Life-threatening conseque nces; urgent intervention ind icated.  
Grade 5  Death related to AE. 
The investigator will determine the severity for each individua l event utilizing the following 
guidance; listed here http://evs.nci.nih.gov/ ftp1/CTCAE/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf :      
Relationship/Relatedness 
The causal relationship between an adverse event and the trial product is assessed by the 
investigator using the following definitions: 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 38 Probable : Good reasons and sufficient docum entation to assu me a causal relationship. 
Possible : A causal relationship is con ceivable and cannot be dismissed  
Unlikely : The event is most likely rela ted to an etiology other than th e trial product. 
An adverse event is considered causally related to the use of t he trial product when the relationship 
assessment is probable or possible. Events assessed as unlikely  related to the use of trial product 
will be considered as having no r elationship to treatment. 
Outcome 
The outcome of an adverse event is assessed by the investigator  using the following definitions: 
Recovered : Fully recovered, or by medical or surgical treatment the cond ition has returned to 
the level observed at the first trial-related activity after th e subject signed the informed consent. 
Recovering : The condition is improving and the subject is expected to rec over from the event. 
This term should only be used when t he subject has completed th e trial. 
Recovered with sequelae : As a result of the AE the subject suffered persistent and sig nificant 
disability/incapacity (e.g. became blind, deaf, paralyzed). Any  AE recovered with sequelae 
should be classified as an SAE. 
Not recovered : The subject’s condition has not i mproved and the symptoms are  unchanged 
Unknown : The subject’s condition is unknow n. This term should only be used when no other 
definition is possibl e e.g., the subject is lost to follow-up. 
10.2 Collection, Recording and Re porting of Adverse Events 
All events meeting the definition of an adverse event must be c ollected and reported from the first 
trial-related activity after the subject signs the informed con sent and until, for example, last subject 
contact/visit/end of post-tr eatment follow-up period.  
At each contact with the trial center, the subject must be aske d about adverse events in an objective 
manner like: “Have you experienced any problems since the last contact?” 
Adverse events according to the  definition, either observed by the investigator or reported by the 
subject, must be recorded by the investigator and evaluated.  A dverse events must be recorded in 
the case report forms. For serious  adverse events, the SAE form  must also be filled in. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 39 The investigator should record the diagnosis, if available. If no diagnosis is available, the 
investigator should record each sign and symptom as individual adverse events.   
Serious Adverse Events 
The investigator must report init ial information on all serious  adverse events within 24 hours of 
obtaining knowledge of the event.  
Furthermore, the investigator must complete and transmit, as ap plicable, the adverse event and 
SAE forms within five days of obtaining knowledge of the SAE. T he monitor must be informed 
accordingly. 
The Investigator will inform the health authorities and indepen dent ethics committees (IECs)/IRBs 
in accordance with local requirements in force and the Internat ional Conference on Harmonization 
(ICH) guidelines for GCP and the European Union (EU) Directive 2001/20/EC / Food and Drug 
Administration (FDA) Title 21 Code of Federal Regulations, Part  312.32 (5). 
Adverse Events Starting after Trial Completion 
Adverse events occurring after trial completion, which the inve stigator considers to be related to 
the investigational medicinal product must be rep orted to the s ponsor.  
10.3 Study-Specific Guidance Pertaining to Adverse Events 
Patient interactions, including ex aminations, tests, procedures  and treatments that are ordered 
based on the occurrence of cirrhosis decompensation or hemorrha gic events are captured in the 
CRF in the Concomitant Treatment , Platelet Function, Unschedule d Visits, and/or Comments 
Modules.    
10.3.1  Variceal Bleeding 
In most cases, an occurrence of a  gastrointestinal hemorrhage d uring the treatment phase will meet 
the definition of an adverse event. Since variceal bleeds are a n endpoint of the  study, specific 
details surrounding such an occurr ence are collected on a dedic ated module of the CRF.  However, 
the same event is also added to the Adverse Event module of the  CRF so that safety listings for the 
study are complete. 
Incidences of variceal bleeds will also follow the protocol for  general bleeding as directed below 
in Section 10.3.3.    
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 40 10.3.2  Cirrhosis Decompensation 
All events that are considered decompensation events related to  cirrhosis meet the definition of an 
adverse event and are captured accordingly.  The following are recognized decompensation events:  
 Ascites 
 Hepatorenal syndrome (HRS) 
 Spontaneous bacterial peritonitis (SBP) 
 Hepatic encephalopathy (HE) 
 Gastric or esophageal variceal bleeding 
Of these events, only the occurrence of variceal bleeding is an  endpoint of the study and is 
captured in a dedicated CRF module in addition to the AE module .  All other decompensation 
events will be captured in the A E module and monitored closely.    
 
10.3.3  Clinical Bleeding Events 
Immediately following a diagnosis  of a clinical bleed during th e treatment or f ollow-up periods, 
and, if possible, prior to any resulting medica l intervention, a whole blood sample is collected in a 
sodium citrate tube and the sample  is evaluated for platelet fu nction by either ROTEM or TEG 
technology, as described in Section 8.2.1.2.   
Any clinical presentation of a h emorrhagic event, including var iceal bleeding, procedural 
complications and hematomas, is reported as an AE and monitored  closely.  Depending on the 
clinical presentation and available test results, possible even t terms may include a clinical term 
(e.g., post-procedural b leeding) or a laboratory-based term (e. g., thrombocytopathy, 
thrombocytopenia, etc.) accordi ng to the Investigator’s assessm ent.   
As noted in 10.3.1 , variceal bleeding will also be r eported in a dedicated CRF mo dule.   
10.4 Subject or Study Discontinuatio n Due to Adverse Event 
In the event that three or more patients experience a grade 3 ( CTCAE) or above from one system 
organ class, regardless of the e vents’ relative attribution to study drug by the Investigator, 
additional enrollment will be halted immediately and an unblind ed safety review of patient data 
will be initiated according to the study’s safety plan.  The ou tcome of this review will be 
documented and communicated to th e Investigators.  Potential ou tcome may include termination 
of the study, modification of t he protocol, or resuming of the protocol without modification.        
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 41 10.5 Follow-up of Adverse Events 
Follow-up of Non-Serious Adverse Events 
All adverse events classified as non-serious adverse events tha t are both severe and possibly or 
probably related to the investig ational medicinal product shoul d be followed until the subject has 
recovered. 
For cases of chronic conditions, follow-up until “recovered” is  not required.  Aft er the subject has 
completed the trial, these cases  can be closed with the outcome  “recovering” or “not recovered”. 
All other non-serious adverse events must be followed until the  outcome of the event is 
“recovering” (for chronic conditions), “recovered” or until, fo r example, last subject 
contact/visit/end of post-treatment follow-up period, whichever  comes first, and until all queries 
related to the adverse ev ent have been resolved. 
Follow-up of Serious Adverse Events 
All adverse events classified as serious should  be followed unt il the outcome of the event is 
“recovered”, “recovered with sequelae”, “death” and until all q ueries have been resolved. For cases 
of chronic conditions and cancer, follow-up until “recovered”, “recovered with sequelae” or 
“death” is not required. After the subject has completed the tr ial, these cases can be closed with 
the outcome “recovering ” or “not recovered”. 
11 STATISTICAL METHODS AND DATA ANALYSIS 
There is no statistical analysis plan for this study and a bios tatistician was not consulted in the 
study design. Results will be ana lyzed and reported descriptive ly.  
11.1 Sample Size Determination 
Formal sample size calculations were not performed. Twenty acti ve, and ten placebo subjects will 
be enrolled in this study and results will be presented descrip tively.   
11.2 Subject Population(s) for Analysis 
All data will be listed by subject. Continuous data will be sum marized in tables comparing 
proportions or percentages of patients in each treatment group.  Standard deviation or standard error 
will also be calculated. The safety population consists of all subjects who were enrolled and 
received at least a partial dos e of IMP; no treated subjects wi ll be excluded from the safety analysis 
population. For the efficacy analyses on this pilot study, pati ents will be evaluated according to the 
treatment they received.   
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 42 11.3 Statistical Methods 
In presenting data fro m this trial, continuous data will be sum marized in tables listing the mean, 
standard deviation or standard e rror, median, and number of sub jects in a group. Categorical data 
will be summarized in tables listing the frequency and the perc entage of subjects in a group. These 
summaries will be presented separ ately for subjects in the Ifet roban and placebo treatment arms.  
11.4 Interim Analysis 
No interim analyses are planned. 
12 STUDY MANAGEMENT AND  DATA COLLECTION 
12.1 Confidentiality 
All information regarding the na ture of the proposed investigat ion provided by the Sponsor or 
Study Monitor to the Investigator  (with the exception of inform ation required by law or regulations 
to be disclosed to the IRB, the subject, or the appropriate reg ulatory authority) must be kept in 
confidence by the Investigator. 
The anonymity of participating subjects must be maintained. Sub jects will be identified by an 
assigned subject number on CRFs and other study documents submi tted to the Study Monitor. 
Documents that will not be submitted to the Study Monitor and t hat identify the subject (e.g., the 
signed informed consent document) must be maintained in strict confidence by the Investigator, 
except to the extent necessary to allow auditing by the appropr iate regulatory au thority, the Study 
Monitor, or Sponsor  representatives. 
12.2 Source Documents 
Source data are contained in source documents.  Examples of the se original documents, and data 
records include: hospital records, clinical and office charts, laboratory notes, memoranda, subjects’ 
diaries or evaluation checklists,  pharmacy dispensing records, recorded data from automated 
instruments, tracings from the HVPG measurements, copies or tra nscriptions certified after 
verification as being accurate and complete, magnetic media, x- rays, subject files, and records kept 
at the pharmacy, at the laborator ies, and at medico-technical d epartments involved in the clinical 
trial. The Monitor, representatives of the Sponsor and the appl icable regulatory authority will be 
allowed access to source documentation. 
12.3 Case Report Forms 
CRF forms will be available for data entry by the site through RedCAP™, a web-based, electronic 
data entry and reporting platform. Cases will be monitored remo tely and on-site by the sponsor 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 43 according to a written Monitori ng Plan and data will be retriev ed by the monitor for data analysis 
at the sponsor.     
12.4 Records Retention 
According to 21CFR312.62, all CRFs, as well as supporting docum entation and administrative 
records, must be retained by the Investigator for a minimum of two years following notification 
that the appropriate regulator y authority has approved the prod uct for the indication under study, 
notification that the entire clinical investigation will not be  used in support of a marketing 
application, or notification that  the marketing application was  not approved. No study documents 
will be destroyed or moved to a new location without prior writ ten approval from the Sponsor. If 
the Investigator relocates, retires, or withdraws from the clin ical study for any reason, all records 
required to be maintained for t he study should be transferred t o an agreed upon designee, such as 
the Study Monitor, another Investigator, or the institution whe re the study was conducted. 
13 STUDY MONITORING, AUDITING, AND INSPECTING 
13.1 Study Monitoring Plan 
The investigator will permit st udy-related monitoring, audits a nd inspections by the IRB, the 
Sponsor and any applicable  regulatory authority.  
The sponsor will adhere to a written Monitoring Plan in fulfill ing the requirements of ICH/GCP 
guidelines and the CFR to monito r the execution of the study an d the collection of data.  In general, 
the progress of the study will be monitored by using the follow ing methods: 
 Periodic onsite visit (s) by the sponsor representative 
 Telephone communications among the  Investigator, Clinical Monit or and/or Medical 
Monitor, as needed 
 Remote and on-site review by the sponsor representative of CRFs , clinical records and 
regulatory documents 
Details are described in the written monitoring plan.  
14 ETHICAL CONSIDERATIONS 
This study will be conducted according to the standards of ICH,  GCP Guidelines, IRB regulations, 
any applicable government regula tions and procedures. This prot ocol and any amendments will be 
submitted to a properly constituted IRB for approval of the stu dy conduct. 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 44 14.1 Informed Consent 
Written informed consent must be obtained from each subject (or  the subject’s legal 
guardian/representative) before performing any Screening/Baseli ne Period evaluations. The 
signed informed consent document will be retained by the Invest igator, and a signed copy will be 
given to the subject or subject’s  legal guardian/representative . The informed consent document, 
which is prepared by th e Investigator, must have been reviewed and approved by the Sponsor and 
the Investigator’s IRB before the initiation of the study. The document must contain the 
20 elements of informed consent described in 21CFR50.25 and ICH  E6 4.8. In addition, subjects 
of appropriate intellectual maturity should provide written inf ormed assent, as determined by the 
institution’s IRB or lo cal legal requirement. 
14.2 Protocol Compliance 
Investigators must follow the IRB-approved protocol. If the Inv estigator intends to deviate from 
the protocol, the IRB and Spons or should be informed prior to t he deviation.  
In cases where the Investigator decides to deviate from the pro tocol in order to avoid an apparent 
immediate risk to a specific subj ect, the Investigator may proc eed with emergency and appropriate 
treatment at his discretion and the IRB and Sponsor will be not ified as soon as possible afterward. 
In addition, the Investigator will document in the subject’s CR F the reasons for the protocol 
deviation and the e nsuing events. 
Substantive changes in the protocol include changes that affect  the safety of subjects or changes 
that alter the scope of the investigation, the scientific quali ty of the study, the experimental design, 
dosages, assessment variable(s), the number of subjects treated , or the subject selection criteria. 
Such changes must be prepared as a protocol amendment by the Sp onsor. A protocol amendment 
must receive IRB approval before implementation.   
In parallel with the IRB approval process, the protocol amendme nt will be submitted to the 
appropriate regulatory authority as an amendment to the regulat ory submission under which the 
study is being conducted. If a prot ocol amendment requires chan ges in the informed consent 
document, the revised informed c onsent document pr epared by the  Investigator must be approved 
by the Sponsor, Study Monitor, and the IRB. 
14.3 Financial Disclosure 
Each clinical site investigator  will provide the Sponsor with s ufficient, accurate financial 
information in accordance with local and federal regulations to  allow the sponsor to submit 
complete and accurate financial certification or disclosure sta tements to the approp riate regulatory 
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 45 health authorities. Investigator s are responsible for providing  information on financial interest 
during the study and for one year after completion of the study  in accordance with FDA policy 
(Title 21 CFR – PART 54 FINANCIAL DISCLOSURE BY CLINICAL INVEST IGATORS 
Revised as of April 1, 2015). 
14.4 Study Files 
Documentation verifying the Inve stigator’s legal and regulatory  authority and acceptable scientific 
background to conduct the trial wi ll be available at both the s ite and the sponsor b efore shipments 
of IMP are sent to the i nvestigative center.   
Following study initiation, the Inve stigator will maintain adeq uate records to re-cr eate and justify 
the complete conduct of the trial  at a later date. Document inv entory will adhere to ICH/GCP and 
CFR requirements and will include those pertaining to the Inves tigator’s qualifications, inventory 
and handling details of investig ational products , and detailed medical and study histories for all 
subjects.    
15 REFERENCES 
Acquaviva A, Vecchio D, Arezzini B, et al. 2013. Signaling path ways involved in isoprostane-
mediated fibrogenic effects in rat hepatic stellate cells. Free Rad Biol Med. 65:201-7.  
Buck M, Garcia-Tsao G, Groszmann  RJ, et al. Novel inflammatory biomarkers of portal pressure 
in compensated cirrhosis patients. Hepatology . 2014; 59(3):1052-9.   
Deng YQ, Zhao H, Ma AL, et al. 2015. Selected cytokines serve a s potential biomarkers for 
predicting liver inflammation and fibrosis in chronic hepatitis  B patients with normal to mildly 
elevated aminotransferases. Medicine . 94(45): doi 10.1097. 
Graupera M, Gracia-Pagan, Pare s M, et al. 2003. Cyclooxygenase- 1 inhibition corrects endothelial 
dysfunction in cirrhotic rat livers. J Hepatology . 39: 515-21.  
LaVecchia C, Levi F, Lucchini F, et al. 1994. Worldwide pattern s and trends in mortality from liver 
cirrhosis, 1955 to 1990. Annals of Epidemiology . 4(6):480-6. 
Pagliaro L, D‘Amico G, Malizia G, et al. Portal hypertension in  cirrhosis; natural history. In:  
Bosch J, Broszmann R (eds) Portal hypertension: Pathophysiology  and treatment. Blackwell 
Scientific, Cambridge: 72-92.    
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 46 Rodriguez-Vilarruplas A, Lavina B, Garcia-Caldero H, et. al. 20 12. PPARa activation improves 
endothelial dysfunction and reduc es fibrosis and portal pressur e in cirrhotic rats. J of Hepatology . 
56:1033-9. 
Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, et al. 2013.  Terutroban, a TP-receptor 
antagonist, reduces portal pre ssure in cirrhotic rats. Hepatology . 00(00):1-12. 
Snyder N, Gajula L, Xiao SY . 2006. APRI: an easy and validated predictor of hepatic fibrosis in 
chronic hepatitis C. J Clin Gastroenterol . 40(6):535-42.  
Tripathi, D, Therapondos G, Ferguson JW, et al. 2006. Endotheli n-1 contributes to maintenance of 
systemic but not portal haemodyna mics in patients with early ci rrhosis: a randomised controlled 
trial. Gut. 55:1290-5. 
Yokoyama Y , Nimura Y , Nagino M, et al. 2005. Role of thromboxan e in producing hepatic injury 
during hepatic stress.  Arch Surg . 140: 801-7.  
16 SUMMARY OF CHANGES  
Protocol changes in Amendment 02, dated 20Jul2017, as compared to Amendment 01, dated 
28July2016 are as follows:  
 Changes are made throughout the protocol to differentiate betwe en HVPG (a single result 
calculated from the difference of a wedged pressure reading and  a free pressure reading) 
and mean HVPG (the average of three valid HVPG values).  
 The allowable difference in the values between the historical a nd the screening ALP in 
Inclusion Criteri on #2 is increased from 40 to 60 U/L.  
 The upper range for Inclusion C riterion #3 is increased from 16  mmHg to 18 mmHg. 
 Exclusion Criterion #3 is updated to clarify that patients with  a prior history of portal or 
splenic vein thrombosis are elig ible to enroll if they are subs equently confirmed as having 
no occlusive portal or spl enic vein thrombosis. 
 Exclusion Criterion #11 is revis ed to clarify that subjects tak ing chronic suppressive 
therapy for Hepatitis B Virus can be enrolled as long as their infection is not active.    
 The value at which a low platelet count excludes a subject, per  Exclusion Criterion #12, 
is decreased from 80 x 103/µL to 60 x 103/µL.  
IND 125794 5.3.5.1 Clinical Study Protocol  
Cumberland Pharmaceuti cals Inc. Ifetroban Injection and Capsule s 
CPI_IFE-005; Protocol Amendment 02_21Jul2017  Page 47  The allowable screening period is increased fro m seven to fourt een days.  
 The informed consent process is deleted from the Schedule of Ev ents table.  The obtaining 
of informed consent must be performed prior to any study proced ures and therefore does 
not need to be conducted within the 14-day screening period.  T herefore, the consenting 
process is not a screening proce dure per se, but rather precede s screening.  
 Single HVPG readings are performed in sequence at Baseline and Day 90 rather than 
performing readings in triplicate.  The procedure is now finish ed when three sequential 
readings are within 1 mmHg of each other.   
 The Day 1 summary description of HVPG in Table 8.1-1 is updated  to better adhere to the 
actual description in Section 8.2.4.1.      
 A provision is added to the protocol in Section 8.2.2 to allow for baseline values of ALT, 
AST, ALKP and bilirubin to be m easured prior to the screening p eriod in patients without 
available historical values in t he required timeframe.  A footn ote is also added to Table 
8.1-1.  
 The VCTE procedure is added to the screening assessments in Sec tion 8.2.2 for patients 
that are diagnosed with cirrhosis, but not by any of the method s detailed by the protocol 
in the Inclusion Criteria (S ection 7.4.1).  Table 8.1-1 is upda ted accordingly.  
 ROTEM or TEG assessments are added at Day 10.  
 
 